HIF-1α和miR210与子痫前期的相关性研究

目的:研究HIF-1α和miR210与子痫前期的相关性。方法:回顾性分析本院2017年9月至2018年9月收治的子痫前期患者40例作为研究组,并选择本院同期健康妊娠妇女40例作为对照组,观察两组入选者HIF-1α、miR210表达水平;观察研究组中合并胎儿生长受限(FGR)的患者的HIF-1、miR210表达水平与无FGR组患者的对比情况。结果:研究组HIF-1α、miR210表达水平均高于对照组,合并FGR子痫前期患者HIF-1α、miR210表达水平高于无FGR子痫前期,差异有统计学意义,子痫前期发生率与HIF-1α、miR210呈正相关,P<0.05。结论:对于子痫前期诊断可配合HIF-1α和miR210表达水平检测,能够预测患者是否出现子痫前期,有利于对疾病的判断,改善预后,值得在临床上应用。     

Clinical evaluation of colony-stimulating factor 1 receptor inhibitors

Signaling through colony-stimulating factor 1 receptor (CSF1R) regulates the development, differentiation, and activation of mononuclear phagocytic cells. Inhibition of this pathway provides an opportunity for therapeutic intervention in diseases in which these cells play a pathogenic role, including cancers, inflammation, fibrosis, and others. Multiple monoclonal antibodies and small molecule inhibitors targeting CSF1R or its known ligands CSF1 and IL-34 have been clinically tested and are generally well tolerated with side effects associated with on-target macrophage inhibition or depletion. To date, clinical activity of CSF1R inhibitors has been primarily observed in diffuse-type tenosynovial giant cell tumors, a disease characterized by genetic alterations in CSF1 leading to dysregulated CSF1R signaling. Expanded development into novel indications such as chronic graft vs host disease may provide new opportunities to further explore areas where a role for CSF1R dependent monocytes and macrophages has been established. This review presents key findings from the clinical development of 12 CSF1/CSF1R targeted therapies as monotherapy or in combination with immune checkpoint inhibitors and chemotherapy.     

Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation

1. Download : Download high-res image (269KB)
2. Download : Download full-size image

     

The effect of soy protein containing soy isoflavones on serum concentration of cell adhesion molecules: A systematic review and meta-analysis of randomized controlled trials

BackgroundSoy protein in combination with soy isoflavones might reduce the serum concentration of inflammatory mediators. In this study, we attempted to summarize the effect of soy protein combined with soy isoflavones on circulating E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in adults.MethodsClinicaltrials.gov, Web of Science, Cochrane Library, PubMed, and Scopus were searched for English articles with no time limit regarding publication up to December 2020. Thereafter, the mean changes from baseline and their standard deviations (SDs) for both intervention and comparison groups were used to calculate the effect size. We used DerSimonian and Laird random-effects model if the heterogeneity test was statistically significant. Cochran's Q test and I-squared statistic were also used to calculate the statistical heterogeneity of the intervention effects.ResultsEight articles were found as eligible for this study. The treatment duration was between 6 and 24 weeks. Soy isoflavones dose was in a range of 30–112 mg/day and soy protein dose was in a range of 11.25–52 g/day. Overall, taking soy protein supplements containing soy isoflavones was not associated with changes in cell adhesion molecules, E-selectin, ICAM-1, or VCAM-1 (WMD = 0.65, 95 % CI: -2.58, 3.89; p = 0.692; WMD = 2.68, 95 % CI: -0.98, 6.34; p = 0.151; WMD = 2.66, 95 % CI: -6.28, 11.61; p = 0.559, respectively).ConclusionThe combination of soy protein and soy isoflavones was not significantly associated with changes in levels of E-selectin, ICAM-1, and VCAM-1. However, we need more studies with a large sample size and more participants with different age categories in this regard.     

Pannexin 1 channels facilitate communication between T cells to restrict the severity of airway inflammation

1. Download : Download high-res image (165KB)
2. Download : Download full-size image

     

高血压及高血压合并糖尿病的患者血浆可溶性NRP-1与SOD浓度的变化

探讨高血压和高血压合并糖尿病患者血浆可溶性神经纤毛蛋白-1（NRP-1）的浓度与超氧化物歧化酶（SOD）活性的变化。